This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Small-Cap Winners & Losers

Leading Brands (LBIX - Get Report) soared more than 26% on news that the Canada-based company's TrueBlue Blueberry Juice line will be sold by Cincinnati-based grocery-store chain Kroger. The products should hit store shelves within 30 days. Shares were rising 56 cents to $2.70.

PRG-Schultz International, (PRGX - Get Report) an Atlanta-based audit-services firm, sharply narrowed its fourth-quarter losses to $2.9 million, or 43 cents a share, from last year's $175.8 million, or $28.32 a share. Revenue slipped 2.6% to $70.5 million, but this tops the only analyst's estimate of $68 million, according to Thomson Financial. Shares were gaining $1.21, or 11.9%, to $11.35.

PharmaNet Development (PDGI) said it earned $6.8 million, excluding items, or 36 cents a share in the fourth quarter, topping the 20-cent estimates sought by analysts. Last year the company, which sells clinical drug development services, posted income of $9.5 million, or 51 cents a share. Revenue, at $103.6 million, was slightly higher than last year and handily bested the $73.9 million consensus.

Looking ahead, the Princeton, N.J.-based firm expects 2007 adjusted income of $1.06 to $1.21 a share on sales of between $334 million and $339 million. Analysts are looking for $1.08 a share on $313.4 million in revenue. Shares were adding $3.05, or 15%, to $23.37.

Sun-Times Media, (SVN) which publishes The Chicago Sun-Times, among other newspapers, got a lift after announcing an unspecified foreign taxing authority had given it a "favorable review" regarding whether its international-tax liability should be adjusted as of year-end 2006. Shares were up 71 cents, or 17.8%, to $4.70.

Biosante Pharma (BPA) was higher on favorable results from a study of its Elestrin product, which treats menopausal hot flashes, published by the journal Obstetrics & Gynecology. Shares of the Lincolnshire, Ill., company were up 22 cents, or 5%, to $4.59.

Hana Biosciences (HNAB) shares climbed after an analyst with Cantor Fitzgerald upped its rating to buy from hold, citing the fact that four of Hana's drugs are on the brink of advanced-phase testing. Shares were adding 19 cents, or 5%, to $4.

TOR Minerals International (TORM) was falling after the Texas-based maker of pigments and flame retardants had a fourth-quarter loss of $275,000, or 4 cents a share, on sales of $5.4 million. Last year the company broke even on $10.1 million revenue. Shares were losing 60 cents, or 18.6%, to $2.62.

Restore Medical (REST) plummeted on lower-than-expected revenue. The company, which makes medical devices for sleep breathing disorders, said sales dropped 29% from last year to $1.1 million -- about $200,000 under two analysts' targets. Its loss widened to $4.1 million, or 26 cents a share, from $1.7 million, or $1.39 a share, a year ago, beating estimates by 2 cents. Still, shares of the St. Paul, Minn., company were falling 79 cents, or 19.2%, to $3.35.

Credit-services firm Intersections (INTX) dropped on lower fourth-quarter profits. The Chantilly, Va., company said it earned only $639,000, or 4 cents a share, compared with $4 million, or 23 cents a share, a year ago. Revenue, at $54.7 million, is 27% higher than last year and squares with Street estimates. The company said it faced $1.2 million in severence payments to former executives, and also faced a large number of credit card declines at one of its clients, hitting it for another $1.4 million. Shares were down $1.55, or 13.4%, to $10.

Drugmaker Icagen (ICGN) broadened its fourth-quarter losses by 4 cents from last year to 28 cents a share, or $6.2 million, on revenue that sank 36% to $1.3 million. Shares of the North Carolina-based company were off 29 cents, or 12.4%, to $2.05.

Pico Holdings (PICO) stumbled after announcing it will sell about 2.8 million newly minted company shares at $37 a share to institutional investors. Net proceeds are expected at bring in around $100.2 million. Shares were dropping $3.32, or 7.9%, to $38.78.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SVN $0.00 0.00%
LBIX $2.18 4.90%
PRGX $4.75 1.70%
AAPL $95.49 2.00%
FB $117.93 -0.54%


Chart of I:DJI
DOW 17,770.49 -120.67 -0.67%
S&P 500 2,063.10 -18.33 -0.88%
NASDAQ 4,772.3240 -45.27 -0.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs